TherapeuticsMD (TXMD)
(Real Time Quote from BATS)
$1.89 USD
+0.01 (0.27%)
Updated Aug 30, 2024 02:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
TherapeuticsMD, Inc. [TXMD]
Reports for Purchase
Showing records 1 - 20 ( 25 total )
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Proof of Life; Annovera Gets Back Into Growth Mode
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Path Forward Not Clear As Acquisition by EW Terminated After Unsuccessful Tender; Rating & Price Target Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Questions Persist After 1Q Results; Price Target Down to $4 on Lowered Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Annovera Supply Issue Causes 4Q21 Miss but New Direction Makes for a Promising 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
vitaCare Divestiture Gives TherapeuticsMD a Much-Needed Shot in the Arm; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
A New Day for TherapeuticsMD: Major Leadership and Strategic Changes Announced; Reiterate Buy, PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Respectable Growth in 2Q Expected to Continue Through 2H21 as Strategy Appears to be Paying Off
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Promising Trends But Portfolio Still Impacted by COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
4Q20 Revenue Beat and Stronger Balance Sheet Poise Portfolio for Growth in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Model Updates to Reflect Lower Revenues Due to Continued COVID-19 Overhang; Reiterate Buy, Lower PT to $4.
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
TherapeuticsMD Hits $20M Revenue Covenant for 4Q, Strong Growth for Annovera and Imvexxy Projected in 2021; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Earnings Beat in Encouraging Quarter Across Portfolio; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Annovera Shows Momentum Which Should Bolster Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Annovera Becomes the Focus for Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
Annovera Moves to Forefront, We Expect Recovery of Momentum by Year-End; Reiterate Buy, Target Goes to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: TherapeuticsMD, Inc.
Industry: Medical - Drugs
No Surprise as Guidance Is Pulled as Covid-19 Creates Uncertainty; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D